Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). The positive results from the GALILEO study confirm the results of the similarly designed Phase 3 ...

Anyone suffering from colds, flu, sinusitis, allergies, croup and chronic dryness knows the soothing power of warm vapor. Vapore, Inc. has brought a new dimension to this relief with its innovative, over-the-counter (OTC) sinus therapy device, MyPurMist™.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). The positive results from the GALILEO study confirm the results of the similarly ...

Bayer HealthCare signed an extension of its agreement with the World Health Organization (WHO) to fight Chagas disease, a deadly and neglected tropical disease (NTD). The five-year extension will come into effect in April 2012, when the previous agreement signed in 2007 had been set to expire. By prematurely concluding ...

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

Bayer HealthCare Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises ...

German chemicals giants Bayer and BASF said Thursday they were teaming up to produce genetically modified rice seeds, technology than can boost yields but which is criticised by environmentalists.

Cancer Targeted Technology (CTT), a Seattle-based biotechnology firm focusing on small molecule cancer enzyme inhibitors for the generation of novel diagnostics and therapeutics, today announced that it has signed a Research and License Option Agreement with Bayer Pharma AG, Germany. Under the agreement, CTT will work with Bayer to optimize ...

Biochemist and protein crystallographer Dr. Oliver Daumke of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, has won the "Bayer Early Excellence in Science Award 2010" in the biology category. He will receive the prize worth EUR 10,000 for his contributions to the understanding of the structure and ...

(Helmholtz Association of German Research Centres) Biochemist and protein crystallographer Dr. Oliver Daumke of the Max Delbrueck Center Berlin-Buch, Germany, has won the Bayer Early Excellence in Science Award 2010 in the biology category. He will receive the prize worth $13,600 for his contributions to the understanding of the structure ...

Bayer today announced the results from the pivotal, double-blind Phase III, ROCKET AF trial. In the study, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF).

Bayer HealthCare is introducing a fitness program to help children ages 7-12 and young adults ages 13-16 with hemophilia A live active lives. "Living Fit! A Joint Effort" is a unique strength training, fitness and wellness program created to increase awareness of the importance of exercise and nutrition among ...